MNPR
NASDAQ · Biotechnology
Monopar Therapeutics Inc
$95.72
-0.75 (-0.78%)
Open$97.92
Previous Close$96.47
Day High$98.19
Day Low$94.95
52W High$124.82
52W Low$50.07
Volume—
Avg Volume119.1K
Market Cap680.95M
P/E Ratio—
EPS$-2.17
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-56.8% upside
Current
$95.72
$95.72
Target
$41.31
$41.31
$22.89
$41.31 avg
$45.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 251.96M | 240.93M | 249.50M |
| Net Income | -49,856,785 | -48,544,141 | -56,777,530 |
| Profit Margin | -19.8% | -20.2% | -22.8% |
| EBITDA | -96,691,861 | -80,803,710 | -82,101,366 |
| Free Cash Flow | -37,656,070 | -41,639,536 | -51,685,705 |
| Rev Growth | +2.3% | +24.0% | -9.1% |
| Debt/Equity | 0.25 | 0.23 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |